Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population

Pharmacogenetics

Volumn 9, Issue 6, 1999, Pages 715-723

  Griese, E U ^a   Asante Poku, S ^c   Ofori Adjei, D ^c   Mikus, G ^a   Eichelbaum, M ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF GHANA   (Ghana)

Author keywords

6CYP2D6; Alleles; Function; Ghanaians

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE; SPARTEINE;

ADULT; ARTICLE; CAUCASIAN; DRUG CLEARANCE; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENOTYPE; GHANA; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; NORMAL HUMAN; PHARMACOGENETICS; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; STATISTICS;

EID: 0033408498     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199912000-00006     Document Type: Article

References (26)

1. Aklillu E, Persson I, Bertilsson, L, Johansson, I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an lithopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278:441-446.
2. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29:192-208.
3. Bock KW, Schrenk D, Foster A, Griese EU, Mörike K, Brockmeier D, Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2, and UDP-glucuronosyltransferases in man using sparteine, caffeine and paracetamol as probes. Pharmacogenetics 1994; 4:209-218.
4. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
5. Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chines and Caucasians. Pharmacogenetics 1998; 8:325-333.
6. Eichelbaum M, Woolhouse NM. Interethnic differences in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol 1985; 28:79-83.
7. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990; 46:377-394.
8. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16:183-187.
9. Eichelbaum M, Bertilsson L, Säwe J, Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 1982; 31:184-186.
10. Evans WE, Relling MV, Rahmann A, McLeod HL, Scott EP, Lin JS. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 1993; 91:2150-2154.
11. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8:15-26.
12. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336:529-532.
13. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90:11825-11829.
14. Leathart JBS, London SJ, Steward A, Adams JD, Idle JR, Daly AK. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998; 8:529-541.
15. Lennard MS, Iyun AO, Jackson PR, Tucker GT, Woods HF. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2:89-92.
16. Meese CO, Thalheimer P, Eichelbaum M. High-performance liquid chromatographic method for the analysis of debrisoquine and its S-(+)-and R-(-) hydroxy metabolites in urine. J Chromatogr 1987; 423:344-350.
17. Masimirembwa C, Hasler J, Bertilsson L, Johansson I, Ekberg O, Ingelman-Sundberg M. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 drugs. Eur J Clin Pharmacol 1996a; 51:117-122.
18. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996b; 42:713-719.
19. Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 1997; 52:1034-1040.
20. Rosin P, Rammler E, Sperling K. Kerngrößenprobleme des kohlenstaubs und ihre bedeutung für die vermahlung. Bericht der technischwissenschaftlichen sachverständigen-ausschüsse des reichskohlerates C-52, Berlin, VDI Verlag; 1933.
21. Simooya OO, Njunju E, Hodjegan AR, Lennard MS, Tucker GT. Debrisoquine and metoprolol oxidation in Zambians: a population study. Pharmacogenetics 1993; 3:205-208.
22. Sommers De K, Moncrieff J, Avenant J. Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of Southern Africa. Hum Toxicol 1989a; 8:39-43.
23. Sommers De K, Moncrieff J, Avenant J. Non-correlations between debrisoquine and metoprolol polymorphisms in the Venda. Hum Toxicol 1989b: 8; 365-368.
24. Stüven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM. Rapid detection of CYPD6 null alleles by long distance-and multiplex-polymerase chain reaction. Pharmacogenetics 1996; 6:417-421.
25. Weibull W. A statistical distribution of wide applicability. Transactions of the American Society of Mechanical Engineers. J Appl Mech 1951; 73:293-297.
26. Woolhouse NM, Eichelbaum M, Oates NS, Idel JR, Smith RL. Dissociation of co-regulatory control of debrisoquine/ phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 1985; 37:512-521.